New combo aims to bridge blood cancer patients to Life-Saving transplant
NCT ID NCT07148947
First seen Feb 10, 2026 · Last updated Jun 21, 2026 · Updated 20 times
Summary
This phase 2 trial is testing whether adding the drug pacritinib to standard treatments (azacitidine or decitabine) can help more people with advanced myeloproliferative neoplasms (MPN) get a stem cell transplant. The study will enroll 27 adults whose MPN has progressed to a more aggressive phase. The goal is to see if the combination can control the disease long enough to allow for a transplant, which may improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACCELERATED PHASE MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pacritinib (a targeted cancer drug) combined with azacitidine or decitabine (chemotherapy-like drugs)
What this could lead to
If successful, this approach could help more people with advanced myeloproliferative neoplasms become eligible for a potentially life-extending stem cell transplant.
What could go wrong
This is a small, early-phase trial with only 27 participants, so results may not apply broadly. The combination therapy may cause side effects or fail to improve transplant rates.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.